Two Sigma Investments LP Reduces Position in Haemonetics Co. (NYSE:HAE)

Two Sigma Investments LP lowered its holdings in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 24.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 58,799 shares of the medical instruments supplier's stock after selling 18,675 shares during the period. Two Sigma Investments LP owned 0.12% of Haemonetics worth $4,591,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. TD Waterhouse Canada Inc. acquired a new stake in shares of Haemonetics during the fourth quarter worth $25,000. Covestor Ltd raised its position in Haemonetics by 146.8% during the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock worth $58,000 after buying an additional 439 shares during the last quarter. Whittier Trust Co. purchased a new position in Haemonetics during the 4th quarter worth $62,000. Parkside Financial Bank & Trust lifted its stake in shares of Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after acquiring an additional 240 shares during the period. Finally, AlphaQuest LLC boosted its holdings in shares of Haemonetics by 36,520.0% in the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock valued at $143,000 after acquiring an additional 1,826 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on HAE shares. JMP Securities reiterated a "market outperform" rating and set a $100.00 price target on shares of Haemonetics in a research note on Tuesday, May 20th. Needham & Company LLC reduced their price target on Haemonetics from $104.00 to $84.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Barrington Research dropped their price objective on Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Raymond James restated a "strong-buy" rating and set a $105.00 target price (down from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. Finally, Bank of America downgraded shares of Haemonetics from a "neutral" rating to an "underperform" rating and cut their price target for the company from $95.00 to $68.00 in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $97.89.

Haemonetics Price Performance

Haemonetics stock traded down $0.16 during trading hours on Friday, hitting $67.68. The stock had a trading volume of 824,062 shares, compared to its average volume of 680,964. Haemonetics Co. has a 1-year low of $55.30 and a 1-year high of $94.99. The stock has a market capitalization of $3.25 billion, a price-to-earnings ratio of 26.65, a PEG ratio of 1.11 and a beta of 0.32. The stock's fifty day moving average is $63.36 and its two-hundred day moving average is $70.53. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 EPS for the quarter, topping the consensus estimate of $1.22 by $0.02. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. The business had revenue of $330.60 million for the quarter, compared to analyst estimates of $329.38 million. During the same period in the previous year, the firm earned $0.90 EPS. The business's revenue for the quarter was down 3.5% compared to the same quarter last year. As a group, analysts predict that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.